| Cash Flow | 2025-07-31 |
|---|---|
| Net loss | -1,742,691 |
| Amortization | 0 |
| Stock-based compensation | 108,399 |
| Gain on sale of product candidates and related assets | 0 |
| Impairment of investment in preferred stock of oragenics, inc | 0 |
| Loss from change in fair value of oragenics, inc. common stock | -459,417 |
| Financing costs paid with issuance of common stock | 0 |
| Allowance for research and development rebate due from australian government | 22,625 |
| Amortization of debt discount and closing costs | 50,965 |
| Decrease in prepaid expenses and other current assets | -6,990 |
| Decrease in research and development rebate due from australian government | 0 |
| Increase (decrease) in accounts payable | 228,379 |
| Increase in accrued wages | 320,838 |
| Increase in accrued interest | 197,686 |
| Net cash used in operating activities | -347,392 |
| Cash proceeds from sale of assets | 0 |
| Cash proceeds from sale of oragenics, inc. common stock, net of commission and fees | 69,787 |
| Net cash provided by investing activities | 69,787 |
| Proceeds from notes payable | 300,000 |
| Principal payments made on notes payable | 0 |
| Proceeds from equity financing | 0 |
| Deferred closing costs | 5,690 |
| Net cash provided by financing activities | 294,310 |
| Increase (decrease) in cash | 16,705 |
| Cash and cash equivalents at beginning of period | 2,379 |
| Cash and cash equivalents at end of period | 19,084 |
Odyssey Health, Inc. (ODYY)
Odyssey Health, Inc. (ODYY)